Sangamo Therapeutics (SGMO) Given Neutral Rating at Wedbush

Wedbush reiterated their neutral rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report published on Monday. Wedbush currently has a $6.00 target price on the biopharmaceutical company’s stock. Wedbush also issued estimates for Sangamo Therapeutics’ FY2022 earnings at ($1.21) EPS.

Other research analysts have also issued reports about the stock. Piper Jaffray Companies set a $25.00 price target on shares of Sangamo Therapeutics and gave the company a buy rating in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Sangamo Therapeutics from a hold rating to a buy rating in a report on Friday, December 29th. Zacks Investment Research upgraded shares of Sangamo Therapeutics from a hold rating to a buy rating and set a $14.00 price objective for the company in a report on Wednesday, November 15th. Finally, Barclays assumed coverage on shares of Sangamo Therapeutics in a report on Wednesday, November 22nd. They issued an overweight rating and a $20.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has an average rating of Buy and an average target price of $18.83.

Sangamo Therapeutics (NASDAQ:SGMO) opened at $23.00 on Monday. The firm has a market cap of $1,940.00, a PE ratio of -33.33 and a beta of 2.87. Sangamo Therapeutics has a 12 month low of $3.65 and a 12 month high of $23.20. The company has a quick ratio of 5.64, a current ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $11.81 million for the quarter, compared to analyst estimates of $10.37 million. Sangamo Therapeutics had a negative net margin of 157.66% and a negative return on equity of 31.81%. Sangamo Therapeutics’s quarterly revenue was up 333.0% compared to the same quarter last year. During the same period last year, the company posted ($0.27) EPS. equities analysts anticipate that Sangamo Therapeutics will post -0.73 earnings per share for the current fiscal year.

In other news, Director Steven J. Mento sold 11,520 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $20.59, for a total transaction of $237,196.80. Following the completion of the sale, the director now owns 5,000 shares in the company, valued at approximately $102,950. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Curt A. Herberts III sold 16,630 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 84,953 shares of company stock valued at $1,544,843. 5.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its holdings in shares of Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 832 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Sangamo Therapeutics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock worth $2,353,000 after buying an additional 1,558 shares during the last quarter. Voya Investment Management LLC increased its holdings in shares of Sangamo Therapeutics by 10.7% during the 2nd quarter. Voya Investment Management LLC now owns 33,809 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 3,270 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Sangamo Therapeutics by 29.3% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 18,962 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 4,300 shares during the last quarter. Finally, Nationwide Fund Advisors increased its holdings in shares of Sangamo Therapeutics by 13.5% during the 3rd quarter. Nationwide Fund Advisors now owns 44,892 shares of the biopharmaceutical company’s stock worth $673,000 after buying an additional 5,337 shares during the last quarter. Institutional investors and hedge funds own 64.22% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/16/sangamo-therapeutics-sgmo-given-neutral-rating-at-wedbush.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply